Huayuan Securities released a research report on April 25 stating that it gave Kunming Pharmaceutical Group (600422.SH) a purchase rating. The main reasons for the rating include: 1) deepening the 37 industrial chain and strategically positioning the Yinfa economy; 2) Kunming traditional Chinese medicine for more than 600 years to create a leader in fine Chinese medicine. (Mainichi Keizai Shimbun)
华源证券4月25日发布研报称，给予昆药集团（600422.SH）买入评级。评级理由主要包括：1）深耕三七产业链，战略定位银发经济；2）六百余年昆中药，打造精品国药领先者。（每日经济新闻）
Huayuan Securities released a research report on April 25 stating that it gave Kunming Pharmaceutical Group (600422.SH) a purchase rating. The main reasons for the rating include: 1) deepening the 37 industrial chain and strategically positioning the Yinf
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.